Predictive Biomarkers for Response to Nivolumab in Head and Neck Squamous Cell Carcinoma
NCT03652142
·
clinicaltrials.gov ↗
UNKNOWN
Status
50
Enrollment
OTHER
Sponsor class
Conditions
HNSCC
DNA Damage
DNA Double Strand Break
Interventions
OTHER:
Biomarker Research
DRUG:
Nivolumab
Sponsor
Attikon Hospital